Literature DB >> 32479195

Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study.

G Kees Hovingh1, Norman E Lepor2, David Kallend3, Robert M Stoekenbroek3, Peter L J Wijngaard3, Frederick J Raal4.   

Abstract

Entities:  

Keywords:  ALN-PCS; cholesterol, LDL; hypercholesterolemia

Year:  2020        PMID： 32479195     DOI： 10.1161/CIRCULATIONAHA.119.044431

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  14 in total

Review 1.  PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection.

Authors:  Natalie Arnold; Wolfgang Koenig
Journal:  Curr Cardiol Rep       Date:  2022-09-10       Impact factor: 3.955

Review 2.  RNA-based therapy in the management of lipid disorders: a review.

Authors:  Dirk Jacobus Blom; Adrian David Marais; Rajen Moodley; Nico van der Merwe; Alet van Tonder; Frederick Johan Raal
Journal:  Lipids Health Dis       Date:  2022-04-23       Impact factor: 4.315

Review 3.  The growth of siRNA-based therapeutics: Updated clinical studies.

Authors:  M May Zhang; Raman Bahal; Theodore P Rasmussen; José E Manautou; Xiao-Bo Zhong
Journal:  Biochem Pharmacol       Date:  2021-01-26       Impact factor: 6.100

4.  Development of an AAV9-RNAi-mediated silencing strategy to abrogate TRPM4 expression in the adult heart.

Authors:  Rebekka Medert; Andreas Jungmann; Staffan Hildebrand; Martin Busch; Dirk Grimm; Veit Flockerzi; Oliver J Müller; Patrick Most; Dagmar Schumacher; Marc Freichel
Journal:  Pflugers Arch       Date:  2021-02-13       Impact factor: 3.657

5.  Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia.

Authors:  Brian Tomlinson; Nivritti Gajanan Patil; Manson Fok; Christopher Wai Kei Lam
Journal:  Endocrinol Metab (Seoul)       Date:  2021-04-19

Review 6.  Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS).

Authors:  Laura D'Erasmo; Simone Bini; Marcello Arca
Journal:  Curr Atheroscler Rep       Date:  2021-09-01       Impact factor: 5.113

Review 7.  RNA Silencing in the Management of Dyslipidemias.

Authors:  Neil C Henney; Maciej Banach; Peter E Penson
Journal:  Curr Atheroscler Rep       Date:  2021-09-01       Impact factor: 5.113

Review 8.  Is Liver Transplant Curative in Homozygous Familial Hypercholesterolemia? A Review of Nine Global Cases.

Authors:  Mohammed Al Dubayee; Meral Kayikcioglu; Jeanine Roeters van Lennep; Nadia Hergli; Pedro Mata
Journal:  Adv Ther       Date:  2022-04-26       Impact factor: 4.070

Review 9.  Advancements in the Treatment of Homozygous Familial Hypercholesterolemia.

Authors:  Archna Bajaj; Marina Cuchel
Journal:  J Atheroscler Thromb       Date:  2022-04-24       Impact factor: 4.394

Review 10.  Inclisiran: First Approval.

Authors:  Yvette N Lamb
Journal:  Drugs       Date:  2021-02       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.